The effect of omarigliptin on glucose excursion using continuous glucose monitoring in the elderly patients with type2 diabetes

The effect of omarigliptin on glucose excursion using continuous glucose monitoring in the elderly patients with type2 diabetes - The effect of omarigliptin on glucose excursion using CGM in the elderly patients with T2DM

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021815

Enrollment

Registered

2016-06-10

Start date

2016-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

omarigliptin 12.5mg or 25mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients with type 2 diabetes, 60 years of age and older

Exclusion criteria

Exclusion criteria: Type 1 diabetes Severe liver dysfunction The subjects found offensive by attending physicians for this clinical research

Design outcomes

Primary

Measure	Time frame
glucose excursion using continuous glucose monitoring	—

Secondary

Measure	Time frame
fasting and postprandial glusoce fasting and postprandial CPR fasting and postprandial glucagon LDL-C TG HDL-C	—

Countries

Japan

Contacts

Public ContactYukio Horikawa

Gifu University Graduate School of Medicine Department of Endoclinology

yhorikaw@gifu-u.ac.jp058-230-6000

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026